anti-thymocyte globulin
- Generic Name
- anti-thymocyte globulin
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation
- Conditions
- Type 1 Diabetes MellitusHypoglycemia
- Interventions
- Biological: Allogeneic Islets of Langerhans
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2008-05-08
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT00286624
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
- Conditions
- Kidney Diseases
- Interventions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 165
- Registration Number
- NCT00275535
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Allogeneic Transplantation From Related Haploidentical Donors
- Conditions
- LeukemiaGraft Versus Host DiseaseNHLCLLMDSMalignancyBlood CancerHodgkin's Disease
- Interventions
- Procedure: non-myeloablative hematopoietic cell transplantationDrug: SolumedrolDrug: Diphenydramine
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 16
- Registration Number
- NCT00185692
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
- Conditions
- Adult Acute Erythroid LeukemiaAdult Acute Monoblastic and Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00101140
Bone Marrow Transplantation in Treating Patients With Leukemia
- Conditions
- LeukemiaGraft Versus Host DiseaseLymphoma
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00006451
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic SyndromeChronic Lymphocytic Leukemia
- Interventions
- Procedure: Stem cell transplant
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT00038831
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2001-06-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern Memorial Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00017641
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
- Conditions
- Graft Versus Host DiseaseAplastic Anemia
- First Posted Date
- 2001-06-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern Memorial Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT00017654
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
- Conditions
- Systemic Sclerosis
- First Posted Date
- 2001-05-07
- Last Posted Date
- 2008-09-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00016458
- Locations
- 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00014755
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.